항체 수탁 제조 시장 : 항체 유형별, 사용되는 발현 시스템 유형별, 사업 규모별, 지역별

Antibody Contract Manufacturing Market Distribution by Type of Antibody Manufactured, Type of Expression System Used, Scale of Operation, and Geographical Regions

US $ 4,799 ￦ 6,575,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,589,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,521,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,660,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 항체 수탁 제조 시장 규모는 2035년까지 예측 기간 동안 10%의 연평균 복합 성장률(CAGR)로, 현재 166억 달러에서 2035년까지 470억 달러로 성장할 것으로 예측됩니다.

시장 세분화는 시장 규모와 기회 분석을 다음 매개 변수로 구분합니다.

제조되는 항체 유형별

• 모노클로날
• 이중특이성

사용되는 발현 시스템 유형별

• 포유류
• 미생물

사업 규모별

• 임상
• 상업

지역별

• 북미
• 유럽
• 아시아
• 라틴아메리카
• 중동 및 북아프리카

항체 수탁 제조 시장 : 성장과 동향

최근 수탁 제조 업체는 바이오의약품 시장 전체에 있어서 필수적인 존재가 되고 있습니다. 사용하면 전반적인 제조 비용 절감과 시장 투입까지의 시간 단축 등 다양한 이점을 얻을 수 있기 때문이라고 생각됩니다.실제 이 영역에 종사하는 항체 제조 기업은 치료용 항체의 전체적인 수요에 대응하기 위해 다른 기업과 적극적으로 협력하여 기존의 능력과 능력을 확대하고 있습니다.

1986년 Orthoclone OKT3(R)이 승인된 이래, 단일클론항체는 현대 헬스케어의 중요한 부분이 되고 있습니다. 실제로, 단일클론항체는 바이오 의약품 산업의 핵심이라고 생각하는 전문가도 있습니다. 이중 특이성 항체와 항체 단편 기반 제품 등 선진적인 변이체가 꾸준히 보급되고 있기 때문에 이 동향은 가까운 미래에도 변할 것 같지 않습니다.

항체 수탁 제조 시장 : 주요 인사이트력

이 보고서는 항체 수탁 제조 시장의 현재 상태를 파악하고 업계 내 잠재적 성장 기회를 확인합니다.

• 현재, 125개사 이상의 수탁 제조업자가 세계 항체 제조 서비스를 제공하고 있다고 주장하고 있으며, 서비스 제공업체의 74%가 상업 규모로 단일클론항체를 제조하고 있습니다.
• 현재 시장 환경은 단편화되고 있어 대기업과 신규 참가 기업의 양쪽이 존재합니다. 이들 대부분은 북미를 거점으로 하는 중견 기업(43%)입니다.
• 이 분야에서 경쟁우위성을 획득하기 위해 이해관계자는 각각의 포트폴리오를 강화하기 위해 기존 능력을 적극적으로 업그레이드하고 새로운 능력을 추가하고 있습니다.
• 능력을 향상시키고 설비를 업그레이드하기 위한 지속적인 노력은 신제품 개발 이니셔티브의 기준이 되는 업계 벤치마크의 확립으로 이어지고 있습니다.

• 이 영역에서의 이해 관계자의 관심의 고조는 제휴 활동 증가로부터도 분명하고, 제휴의 대부분은 항체 제조에 초점을 맞추었습니다.
• 이 연구 분야에 대한 핵심 역량을 강화하기 위해 CMO는 기존 인프라를 업그레이드하고 각각의 제조 능력을 확대하기 위해 적극적으로 투자하고 있습니다.
• 세계의 항체 수탁 제조 능력은 다양한 지역에 분산되어 있지만, 그 55% 이상은 북미의 제조 시설에 있습니다.
• 다양한 개발 단계에서 평가되고 있는 항체 기반의 의약품 및 치료제 후보가 몇 가지 있는 것으로부터, 향후 10년간에 이러한 제품 수요는 대폭 증가할 것으로 예측됩니다.
• 항체 제조 시장은 2035년까지 연평균 복합 성장률(CAGR) 10%로 성장할 것으로 예상됩니다.

항체 수탁 제조 시장 : 주요 부문

제조되는 항체 유형별로는 시장은 단일클론항체와 이중 특이성 항체로 구분됩니다.

사용되는 발현 시스템 유형별로는 시장은 포유류 발현 시스템과 미생물 발현 시스템으로 구분됩니다.

사업 규모별로 시장은 임상 규모와 상업 규모로 구분됩니다. 현재, 세계의 항체 수탁 제조 시장에서는 항체의 상업 생산에 대한 수요 증가로 상업 규모가 최대의 점유율을 차지하고 있습니다.

주요 지역별로 볼 때 시장은 북미, 유럽, 아시아, 라틴아메리카, 중동, 북아프리카로 구분됩니다.

본 보고서에서는 세계의 항체 수탁 제조 시장에 대해 조사했으며, 시장 개요와 함께 제조되는 항체 유형별, 사용되는 발현 시스템 유형별, 사업 규모별, 지역별 동향 및 시장 진출기업프로파일 등의 정보를 제공합니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제적 및 기타 프로젝트 특유의 고려 사항

제4장 주요 요약

제5장 소개

• 장의 개요
• 항체의 개념
• 항체의 구조
• 항체 아이소유형
• 항체의 작용기전
• 항체의 유형
• 계약 제조 개요
• 바이오의약품업계에서 아웃소싱의 필요성
• 제조 서비스 아웃소싱의 장점

제6장 시장 상황

• 장의 개요
• 항체 수탁 제조업자 : 시장 상황

제7장 기업 경쟁력 분석

제8장 상세한 기업 프로파일

• 장의 개요
• AGC Biologics
• Aldeveron
• Emergent Biosolutions
• Eurofins CDMO
• FUJIFILM Diosynth Biotechnologies
• KBI Biopharma
• Lonza
• Nitto Avecia Pharma Services
• Novasep
• Pierre Fabre
• Samsung Biologics
• Synthon
• Thermo Fisher Scientific

제9장 기업 프로파일 목록

• 장의 개요
• ABL
• Abzena
• Allele Biotechnology &Pharmaceuticals
• Alvotech
• Antibody Production Services
• Arabio
• Bharat Serums and Vaccines
• Boehringer Ingelheim
• Glenmark Pharmaceuticals
• MilliporeSigma
• Siam Bioscience

제10장 사례 연구: 소분자와 대분자(생물 제제)의 약제/치료법의 비교

• 장의 개요
• 소분자 및 생물제제

제11장 벤치마크 분석

• 장의 개요
• 조사 방법
• 항체 수탁 제조업자 : 벤치마크 분석
• 결론

제12장 파트너십 및 협업

제13장 최근 확장

제14장 용량 분석

제15장 수요 분석

제16장 시장 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제17장 세계의 항체 수탁 제조 시장

• 장의 개요
• 주요 전제와 조사 방법
• 세계의 항체 수탁 제조 시장, 과거 동향(2019년 이후) 및 예측(-2035년)
• 주요 시장 세분화

제18장 세계의 항체 수탁 제조 시장(제조되는 항체 유형별)

제19장 세계의 항체 수탁 제조 시장(사업 규모별)

제20장 세계의 항체 수탁 제조 시장(사용되는 발현 시스템 유형별)

제21장 세계의 항체 수탁 제조 시장(주요 지역별)

제22장 SWOT 분석

제23장 항체 수탁 제조 시장의 미래

제24장 주요 인사이트

제25장 부록 2 표 형식 데이터

제26장 부록 3 기업 및 단체 일람

SHW

영문 목차

영문목차

ANTIBODY CONTRACT MANUFACTURING MARKET: OVERVIEW

As per Roots Analysis, the global antibody contract manufacturing market is estimated to grow from USD 16.6 billion in the current year to USD 47 billion by 2035, at a CAGR of 10% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Antibody Manufactured

• Monoclonal
• Bispecific

Type of Expression System Used

• Mammalian
• Microbial

Scale of Operation

• Clinical
• Commercial

Geographical Regions

• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa

ANTIBODY CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

In recent years, contract manufacturers have become an integral part of the overall biopharmaceutical market. This trend is also gaining popularity within the antibody manufacturing market, as developers are increasingly outsourcing their antibody manufacturing requirements to contract service providers. This can be attributed to the fact that employing such third-party service providers offers various advantages, such as a reduction in overall production cost and a decrease in time to market. In fact, antibody manufacturing companies engaged in this domain are actively collaborating with other players and expanding their existing capabilities and capacities in order to cater to the overall demand for therapeutic antibodies.

Since the approval of Orthoclone OKT3(R) in 1986, monoclonal antibodies have become an important part of modern healthcare practices. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. Owing to their high specificity and the favorable safety profile, antibody-based interventions presently constitute the largest class of biologics contract manufacturing market. This trend is unlikely to change in the near future as advanced variants, such as bispecific antibodies and antibody fragment-based products, are steadily gaining traction. Further, the legacy challenges associated with the development and production of biologics, such as advanced supply chain requirements have further boosted the outsourcing antibody production operations.

ANTIBODY CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the antibody contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• Presently, over 125 contract manufacturers claim to offer services for antibody manufacturing across the globe; 74% of the service providers manufacture monoclonal antibodies at a commercial scale.
• The current market landscape is fragmented, featuring the presence of both large players and new entrants; most of these are mid-sized players (43%) based in North America.
• In pursuit of gaining a competitive edge in this field, stakeholders are actively upgrading their existing capabilities and adding new competencies in order to enhance their respective portfolios.
• The ongoing efforts to improve capabilities and upgrade facilities have led to the establishment of industry benchmarks, which serve as a standard for new product development initiatives.

• The growing interest of stakeholders in this domain is evident from the rise in partnership activity; most of the partnerships are focused on antibody manufacturing.
• In order to enhance core competencies related to this field of research, CMOs are actively investing in upgrading existing infrastructure and expanding their respective manufacturing capacities.
• The global installed antibody contract manufacturing capacity is spread across various regions; over 55% of this capacity is available in manufacturing facilities based in North America.
• Given that there are several antibody-based drug / therapy candidates being evaluated across various stages of development, the demand for such products is anticipated to rise significantly over the next decade.
• The antibody manufacturing market is likely to grow at a CAGR of 10%, till 2035; presently, majority of the market share is occupied by North America, followed by Europe.

ANTIBODY CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

Monoclonal Antibodies Segment Occupy the Largest Share of the Global Antibody Contract Manufacturing Market

Based on the type of antibody manufactured, the market is segmented into monoclonal and bispecific antibody. At present, the monoclonal antibody segment holds the maximum share of the global antibody contract manufacturing market. However, players are now increasingly focused on the development of bispecific antibodies for therapeutic use.

By Type of Expression System Used, the Microbial Expression System is the Fastest Growing Segment of the Global Antibody Contract Manufacturing Market

Based on the type of expression system used, the market is segmented into mammalian and microbial expression systems. Currently, the mammalian expression system segment captures the highest proportion of the global antibody contract manufacturing market, owing to the fact that mammalian expression systems allow antibodies to produce higher biological activity and binding affinity.

Commercial Segment Occupy the Largest Share of the Global Antibody Contract Manufacturing Market

Based on the scale of operation, the market is segmented into clinical and commercial scales. At present, the commercial segment holds the maximum share of the global antibody contract manufacturing market owing to the increasing demand for commercial production of antibodies.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Latin America and the Middle East and North Africa. Currently, North America dominates the antibody contract manufacturing market and accounts for the largest revenue share. Additionally, the market in Asia is likely to grow at a higher CAGR in the future.

Example Players in the Antibody Contract Manufacturing Market

• AGC Biologics
• Aldevron
• Emergent BioSolutions
• Eurofins CDMO
• FUJIFILM Diosynth Biotechnologies
• KBI Biopharma
• Lonza
• Nitto Avecia Pharma Services
• Novasep
• Pierre Fabre
• Samsung BioLogics
• Synthon
• Thermo Fisher Scientific

ANTIBODY CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the global antibody contract manufacturing market, focusing on key market segments, including [A] type of antibody manufactured, [B] type of expression system used, [C] scale of operation and [D] geographical regions.
• Market Landscape: A comprehensive evaluation of the companies engaged in antibody contract manufacturing market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] location of manufacturing facilities, [E] scale of operation, [F] type of antibody, [G] type of expression systems used, [H] fill / finish operations and [I] affiliations to regulatory agencies.
• Company Competitiveness Analysis: A comprehensive competitive analysis of antibody contract manufacturers, examining factors, such as [A] company strength and [B] portfolio strength and [C] portfolio diversity.
• Company Profiles: In-depth profiles of key service providers engaged in the antibody contract manufacturing market, focusing on [A] overview of the company, [B] financial information (if available), [C] service portfolio, and [D] recent developments and an informed future outlook.
• Case Study: A detailed comparison of the key characteristics of large and small molecule drugs, along with information on the steps and challenges involved in their respective manufacturing processes.
• Benchmark Analysis: A detailed analysis of the key focus areas of small, mid-sized, large and very large companies by comparing their existing capabilities within and beyond their respective peer groups.
• Capacity Analysis: An insightful analysis of the overall installed capacity for manufacturing antibodies, based on various parameters, such as [A] company size and [B] key geographical regions.
• Demand Analysis: An in-depth analysis of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength.
• SWOT Analysis: An analysis of industry affiliated trends, opportunities and challenges, which are likely to impact the evolution of antibody contract manufacturing market; it includes a Harvey ball analysis, assessing the relative impact of each SWOT parameter on industry dynamics.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Future Estimates
  • 3.2.2. Currency Coverage and Foreign Exchange Rate
    • 3.2.2.1. Major Currencies Affecting the Market
    • 3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
    • 3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
    • 3.2.2.4. Strategies for Mitigating Foreign Exchange Risks
  • 3.2.3. Trade Policies
    • 3.2.3.1. Impact of Trade Barriers on the Market
    • 3.2.3.2. Strategies for Mitigating the Risks associated with Trade Barriers
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Concept of an Antibody
• 5.3. Structure of an Antibody
• 5.4. Antibody Isotypes
• 5.5. Mechanism of Action of Antibodies
• 5.6. Types of Antibodies
  • 5.6.1. Monoclonal Antibodies
  • 5.6.2. Bispecific Antibodies
  • 5.6.3. Polyclonal Antibodies
• 5.7. Overview of Contract Manufacturing
• 5.8. Need for Outsourcing in the Biopharmaceutical Industry
• 5.9. Advantages of Outsourcing Manufacturing Services

6. MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Antibody Contract Manufacturers: Overall Market Landscape
  • 6.2.1. Analysis by Year of Establishment
  • 6.2.2. Analysis by Company Size
  • 6.2.3. Analysis by Location of Headquarters
  • 6.2.4. Analysis by Location of Antibody Manufacturing Facilities
  • 6.2.5. Analysis by Scale of Operation
  • 6.2.6. Analysis by Type of Antibody Manufactured
  • 6.2.7. Analysis by Expression System Used
  • 6.2.8. Analysis by Fill / Finish Services Offered

7. COMPANY COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions and Key Input Parameters
• 7.3. Methodology
• 7.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
• 7.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
• 7.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia-Pacific

8. DETAILED COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. AGC Biologics
  • 8.2.1. Company Overview
  • 8.2.2. Antibody Contract Manufacturing Service Portfolio
  • 8.2.3. Recent Developments and Future Outlook
• 8.3. Aldeveron
  • 8.3.1. Company Overview
  • 8.3.2. Antibody Contract Manufacturing Service Portfolio
  • 8.3.3. Recent Developments and Future Outlook
• 8.4. Emergent Biosolutions
  • 8.4.1. Company Overview
  • 8.4.2. Antibody Contract Manufacturing Service Portfolio
  • 8.4.3. Recent Developments and Future Outlook
• 8.5. Eurofins CDMO
  • 8.5.1. Company Overview
  • 8.5.2. Antibody Contract Manufacturing Service Portfolio
  • 8.5.3. Future Outlook
• 8.6. FUJIFILM Diosynth Biotechnologies
  • 8.6.1. Company Overview
  • 8.6.2. Antibody Contract Manufacturing Service Portfolio
  • 8.6.3. Recent Developments and Future Outlook
• 8.7. KBI Biopharma
  • 8.7.1. Company Overview
  • 8.7.2. Antibody Contract Manufacturing Service Portfolio
  • 8.7.3. Recent Developments and Future Outlook
• 8.8. Lonza
  • 8.8.1. Company Overview
  • 8.8.2. Antibody Contract Manufacturing Service Portfolio
  • 8.8.3. Recent Developments and Future Outlook
• 8.9. Nitto Avecia Pharma Services
  • 8.9.1. Company Overview
  • 8.9.2. Antibody Contract Manufacturing Service Portfolio
  • 8.9.3. Recent Developments and Future Outlook
• 8.10. Novasep
  • 8.10.1. Company Overview
  • 8.10.2. Antibody Contract Manufacturing Service Portfolio
  • 8.10.3. Future Outlook
• 8.11. Pierre Fabre
  • 8.11.1. Company Overview
  • 8.11.2. Antibody Contract Manufacturing Service Portfolio
  • 8.11.3. Recent Developments and Future Outlook
• 8.12. Samsung Biologics
  • 8.12.1. Company Overview
  • 8.12.2. Antibody Contract Manufacturing Service Portfolio
  • 8.12.3. Recent Developments and Future Outlook
• 8.13. Synthon
  • 8.13.1. Company Overview
  • 8.13.2. Antibody Contract Manufacturing Service Portfolio
  • 8.13.3. Recent Developments and Future Outlook
• 8.14. Thermo Fisher Scientific
  • 8.14.1. Company Overview
  • 8.14.2. Antibody Contract Manufacturing Service Portfolio
  • 8.14.3. Recent Developments and Future Outlook

9. TABULATED COMPANY PROFILES

• 9.1. Chapter Overview
• 9.2. ABL
  • 9.2.1. Company Overview
  • 9.2.2. Antibody Contract Manufacturing Service Portfolio
• 9.3. Abzena
  • 9.3.1. Company Overview
  • 9.3.2. Antibody Contract Manufacturing Service Portfolio
• 9.4. Allele Biotechnology & Pharmaceuticals
  • 9.4.1. Company Overview
  • 9.4.2. Antibody Contract Manufacturing Service Portfolio
• 9.5. Alvotech
  • 9.5.1. Company Overview
  • 9.5.2. Antibody Contract Manufacturing Service Portfolio
• 9.6. Antibody Production Services
  • 9.6.1. Company Overview
  • 9.6.2. Antibody Contract Manufacturing Service Portfolio
• 9.7. Arabio
  • 9.7.1. Company Overview
  • 9.7.2. Antibody Contract Manufacturing Service Portfolio
• 9.8. Bharat Serums and Vaccines
  • 9.8.1. Company Overview
  • 9.8.2. Antibody Contract Manufacturing Service Portfolio
• 9.9. Boehringer Ingelheim
  • 9.9.1. Company Overview
  • 9.9.2. Antibody Contract Manufacturing Service Portfolio
• 9.10. Glenmark Pharmaceuticals
  • 9.10.1. Company Overview
  • 9.10.2. Antibody Contract Manufacturing Service Portfolio
• 9.11. MilliporeSigma
  • 9.11.1. Company Overview
  • 9.11.2. Antibody Contract Manufacturing Service Portfolio
• 9.12. Siam Bioscience
  • 9.12.1. Company Overview
  • 9.12.2. Antibody Contract Manufacturing Service Portfolio

10. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES

• 10.1. Chapter Overview
• 10.2. Small Molecules and Biologics
  • 10.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
  • 10.2.2. Comparison of Key Characteristics
  • 10.2.3. Comparison of Manufacturing Processes
  • 10.2.4. Comparison of Key Manufacturing related Challenges

11. BENCHMARK ANALYSIS

• 11.1. Chapter Overview
• 11.2. Methodology
• 11.3. Antibody Contract Manufacturers: Benchmarking Analysis
  • 11.3.1. Benchmark Analysis of Small Players Based in North America (Peer Group I)
  • 11.3.2. Benchmark Analysis of Mid-Sized Players Based in North America (Peer Group II)
  • 11.3.3. Benchmark Analysis of Large Players Based in North America (Peer Group III)
  • 11.3.4. Benchmark Analysis of Very Large Players Based in North America (Peer Group IV)
  • 11.3.5. Benchmark Analysis of Small Players Based in Europe (Peer Group V)
  • 11.3.6. Benchmark Analysis of Mid-Sized Players Based in Europe (Peer Group VI)
  • 11.3.7. Benchmark Analysis of Large Players Based in Europe (Peer Group VII)
  • 11.3.8. Benchmark Analysis of Very Large Players Based in Europe (Peer Group VIII)
  • 11.3.9. Benchmark Analysis of Small Players Based in Asia-Pacific (Peer Group IX)
  • 11.3.10. Benchmark Analysis of Mid-Sized Players Based in Asia-Pacific (Peer Group X)
  • 11.3.11. Benchmark Analysis of Large Players Based in Asia-Pacific (Peer Group XI)
  • 11.3.12. Benchmark Analysis of Very Large Players Based in Asia-Pacific (Peer Group XII)
• 11.4. Concluding Remarks

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Chapter Overview
• 12.2. Partnerships Models
• 12.3. Antibody Contract Manufacturing: List of Partnerships
  • 12.3.1. Analysis by Year of Partnership
  • 12.3.2. Analysis by Type of Partnership
  • 12.3.3. Analysis by Year and Type of Partnership
  • 12.3.4. Analysis by Type of Antibody Manufactured
  • 12.3.5. Analysis by Project Scale
  • 12.3.6. Analysis by Focus Therapeutic Area
  • 12.3.7. Most Active Players: Analysis by Number of Partnerships and Type of Partnership
  • 12.3.8. Geographical Analysis
    • 12.3.8.1. Continent-wise Distribution
    • 12.3.8.2. Country-wise Distribution

13. RECENT EXPANSIONS

• 13.1. Chapter Overview
• 13.2. Antibody Contract Manufacturers: List of Expansions
  • 13.2.1. Analysis by Year of Expansion
  • 13.2.2. Analysis by Type of Expansion
  • 13.2.3. Analysis by Type of Antibody Manufactured
  • 13.2.4. Analysis by Location of Manufacturing Facility
  • 13.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion
  • 13.2.6. Analysis of Most Active Players by Number of Expansions
  • 13.2.7. Geographical Analysis
    • 13.2.7.1. Country-wise Distribution

14. CAPACITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Assumptions and Methodology
• 14.3. Antibody Contract Manufacturing: Installed Global Capacity
  • 14.3.1. Analysis by Scale of Operation
  • 14.3.2. Analysis by Type of Expression System Used
  • 14.3.3. Analysis by Location of Manufacturing Facility
• 14.4. Concluding Remarks

15. DEMAND ANALYSIS

• 15.1. Chapter Overview
• 15.2. Assumptions and Methodology
• 15.3. Antibody Contract Manufacturing Market: Overall Annual Demand
  • 15.3.1. Analysis by Scale of Operation
  • 15.3.2. Analysis by Geography

16 MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 16.1. Chapter Overview
• 16.2. Market Drivers
• 16.3. Market Restraints
• 16.4. Market Opportunities
• 16.5. Market Challenges
• 16.6. Conclusion

17 GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Global Antibody Contract Manufacturing Market, Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
  • 17.3.1. Scenario Analysis
    • 17.3.1.1. Conservative Scenario
    • 17.3.1.2. Optimistic Scenario
• 17.4. Key Market Segmentations

18. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET, BY TYPE OF ANTIBODY MANUFCATURED

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Antibody Contract Manufacturing Market: Distribution by Type of Antibody Manufactured
  • 18.3.1. Antibody Contract Manufacturing Market for Monoclonal Antibodies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 18.3.2. Antibody Contract Manufacturing Market for Bispecific Antibodies: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
• 18.4. Data Triangulation and Validation

19. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Antibody Contract Manufacturing Market: Distribution by Scale of Operation
  • 19.3.1. Antibody Contract Manufacturing Market at Commercial Scale: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 19.3.2. Antibody Contract Manufacturing Market at Clinical Scale: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
• 19.4. Data Triangulation and Validation

20. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Antibody Contract Manufacturing Market: Distribution by Type of Expression System Used
  • 20.3.1. Antibody Contract Manufacturing Market for Mammalian Expression System: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 20.3.2. Antibody Contract Manufacturing Market for Microbial Expression System: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
• 20.4. Data Triangulation and Validation

21. GLOBAL ANTIBODY CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Antibody Contract Manufacturing Market: Distribution by Key Geographical Regions
  • 21.3.1. Antibody Contract Manufacturing Market in North America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 21.3.2. Antibody Contract Manufacturing Market in Europe: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
  • 21.3.3. Antibody Contract Manufacturing Market in Asia: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
  • 21.3.4. Antibody Contract Manufacturing Market in Latin America: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035)
  • 21.3.5. Antibody Contract Manufacturing Market in Middle East and North Africa: Historical Trends (Since 2019) and Forecasted Estimates (Till 2035) (USD Billion)
• 21.4. Data Triangulation and Validation

22. SWOT ANALYSIS

• 22.1. Chapter Overview
• 22.2. Strengths
• 22.3. Weaknesses
• 22.4. Opportunities
• 22.5. Threats
• 22.6. Comparison of SWOT Factors
• 22.7. Concluding Remarks

23 FUTURE OF THE ANTIBODY CMO MARKET

• 23.1. Chapter Overview
• 23.2. Rise in Outsourcing Activity
• 23.3. Shift from One-time Contractual Engagements to Strategic Partnerships
• 23.4. Adoption of New and Innovative Technologies
• 23.5. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
• 23.6. Capability and Expertise Expansions by CMOs to become One Stop Shops
• 23.7. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
• 23.8. Challenges Faced by both Sponsors and Service Providers
• 23.9. Factors Influencing the Future of Antibody Contract Manufacturing Market
• 23.10. Concluding Remarks

24. EXECUTIVE INSIGHTS

• 24.1. Chapter Overview
• 24.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
• 24.3. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
• 24.4. Patrica, Business Development and Marketing Manager, 53 Biologics
• 24.5. Daniel, Business Development Manager, EirGenix
• 24.6. Michiel Stork, Business Development Manager, ProBiogen
• 24.7. Judyta Suskiewicz, Business Development Specialist, Mabion

25. APPENDIX 2: TABULATED DATA

26. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS

관련자료